SHL Medical shortlisted for the CPHI Pharma Awards 2022

SHL Medical is honored to announce that both its modular Fully Automated Testing Machine (FATM) platform and Maggie® 5.0 autoinjector have been selected as potential winners for the 2022 CPHI Pharma Award.  

The award seeks to recognize “Excellence in Pharma” across several categories, assessing entries from the industry’s leading companies in pursuit of innovation and excellence. SHL’s FATM is shortlisted under the Manufacturing, Technology, and Equipment category, whereas Maggie 5.0 is nominated in the Packaging and Drug Delivery category. The results will be announced at a ceremony on-site in Frankfurt on November 1. 

SHL Medical first developed its modular FATM in 2017 after foreseeing the need to create a universal testing machine for different testing requirements of both syringe-based and cartridge-based injection devices. The modular FATM platform features LEGO®-like interchangeable tools and fixtures that enable increased flexibility and versatility of testing methods and parameters, thus providing pharma companies with faster development time, cost optimization, and the opportunity to scale production up (or down) for product lifecycle management. It has currently been implemented to accommodate different testing parameters and to address complex testing sequences for a variety of SHL’s device technologies. 

The Maggie 5.0 autoinjector is SHL’s latest addition to its Needle Isolation Technology (NIT®) family of autoinjectors – paving the way for large volume self-injection therapies. Recent advancements in formulation science have opened new pathways for large-volume drugs to be deliverable through subcutaneous injections. This means the industry is faced with an opportunity to innovate subcutaneous drug delivery in volumes never been considered for autoinjectors before. Maggie 5.0 is a cartridge-based autoinjector for the delivery of large-volume drugs targeting ≤ 5.0 mL fill volumes. The built-in NIT eliminates the need for patients to manually attach the needle during injection – simplifying the whole injection process while underscoring the interconnected importance of patient safety and convenience. The Maggie 5.0 autoinjector is SHL’s response to continuously designing and developing drug delivery technologies that would ultimately enable the patients’ independence – across challenging use cases, disease areas, formulation requirements, and global markets.  

As a leading company in the drug delivery industry, SHL has consistently delivered quality and customer-focused solutions to support bio/pharmaceutical companies in helping patients whose quality of life relies on innovative self-treatment therapies. SHL is delighted for the recognition as it not only celebrates the hard work that our team has put into developing these solutions, but also encourages us to think about what we can further achieve to contribute to the advancement of the drug delivery industry.  

Join SHL at Booth #30A30 in this year’s CPHI Frankfurt conference and learn more about our device solutions and offerings.

About CPHI Pharma Awards 

Since its inception in 2004, the CPHI Pharma Awards has celebrated cross-industry innovators making a contribution to driving the industry forward, through people, products, and performance. The Awards welcomes entries from pharmaceutical and biopharmaceutical companies across the globe, that are engaged in the design, development, manufacture, production, and distribution of both large and small molecule drug products.